Preterm Premature Rupture of Membranes: Perspectives Surrounding Controversies in Management

 

 Buy Article Permissions and Reprints

ABSTRACT

Preterm premature rupture of the membranes (PPROM) occurs in approximately 3% of all pregnancies, and accounts for one third of all preterm births. Despite its prevalence, optimal management of PPROM remains largely undefined and lacks conformity. In this article, we review the pathophysiology of PPROM, and summarize the available literature describing various management strategies in an effort to define current controversies in the management of PPROM.

REFERENCES

• 1 Mercer B M. Preterm premature rupture of the membranes.  Obstet Gynecol. 2003;  101 178-193
  CrossrefPubMedGoogle Scholar
• 2 American College of Obstetricians and Gynecologists Practice Bulletin .Premature Rupture of Membranes. Washington, DC; American College of Obstetricians and Gynecologists June 1998 No. 1
  Google Scholar
• 3 Garite T J. Management of premature rupture of membranes.  Clin Perinatol. 2001;  28 837-844
  PubMedGoogle Scholar
• 4 Parry S, Strauss J F. Mechanisms of disease: premature rupture of the fetal membranes.  N Engl J Med. 1998;  338 663-670
  CrossrefPubMedGoogle Scholar
• 5 Meis P J, Ernest J M, Moore M L. Causes of low birth weight births in public and private patients.  Am J Obstet Gynecol. 1987;  156 1165-1168
  CrossrefPubMedGoogle Scholar
• 6 Goldenberg R L. The management of preterm labor.  Obstet Gynecol. 2002;  100 1020-1037
  CrossrefPubMedGoogle Scholar
• 7 Garite T J. Premature rupture of the membranes: the enigma of the obstetrician.  Am J Obstet Gynecol. 1985;  151 1001-1005
  PubMedGoogle Scholar
• 8 Graham R L, Gilstrap III L C, Hauth J C et al.. Conservative management of patients with premature rupture of fetal membranes.  Obstet Gynecol. 1982;  59 607-611
  PubMedGoogle Scholar
• 9 Capeless E L, Mead P B. Management of preterm premature rupture of membranes: lack of a national consensus.  Am J Obstet Gynecol. 1987;  157 11-12
  CrossrefPubMedGoogle Scholar
• 10 Cox S M, Williams M L, Leveno K J. The natural history of preterm ruptured membranes: what to expect of expectant management.  Obstet Gynecol. 1988;  71 558-562
  PubMedGoogle Scholar
• 11 Schmidt W. The amniotic fluid compartment: the fetal habitat.  Adv Anat Embryol Cell Biol. 1992;  127 1-100
  PubMedGoogle Scholar
• 12 Arias F, Gonzalez-Ruiz A R, Jacobson R L. Recent advances in the pathophysiology and management of preterm premature rupture of the fetal membranes.  Curr Opin Obstet Gynecol. 1999;  11 141-147
  CrossrefPubMedGoogle Scholar
• 13 Casey M L, MacDonald P C. Interstitial collagen synthesis and processing in human amnion: a property of the mesenchymal cell.  Biol Reprod. 1996;  55 1253-1256
  PubMedGoogle Scholar
• 14 Malak T M, Ockleford C D, Bell S C et al.. Confocal immunofluorescence localization of collagen types I, III, IV, V and VI and their ultrastructural organization in term human fetal membranes.  Placenta. 1993;  14 385-406
  CrossrefPubMedGoogle Scholar
• 15 Casey M L, McDonald P C. Interstitial collagen synthesis and processing in human amnion: a property of the mesenchymal cells.  Biol Reprod. 1996;  55 1253-1260
  PubMedGoogle Scholar
• 16 Fortunato S J, Menon R. Screening of novel matrix metalloproteinases (MMPs) in human fetal membranes.  J Assist Reprod Genet. 2002;  19 483-486
  PubMedGoogle Scholar
• 17 Ferrand P E, Parry S, Sammel M et al.. A polymorphism in the matrix metalloproteinase-9 promoter is associated with increased risk of preterm premature rupture of membranes in African Americans.  Mol Hum Reprod. 2002;  8 494-501
  CrossrefPubMedGoogle Scholar
• 18 Fujimoto T, Parry S, Urbanek M et al.. A single nucleotide polymorphism in the matrix metalloproteinase-1 (MMP-1) promoter influences amnion cell MMP-1 expression and risk for preterm premature rupture of the fetal membranes.  J Biol Chem. 2002;  277 6296-6302
  CrossrefPubMedGoogle Scholar
• 19 Woods Jr J R, Plessinger M, Miller R K. Vitamins C and E: missing links in preventing preterm premature rupture of membranes?.  Am J Obstet Gynecol. 2001;  185 5-10
  CrossrefPubMedGoogle Scholar
• 20 McGregor J A, Lawellin D, Franco-Buff A, Todd J K, Makowski E L. Protease production by microorganisms associated with reproductive tract infection.  Am J Obstet Gynecol. 1986;  154 109-114
  PubMedGoogle Scholar
• 21 Hillier S L, Martius J, Krohn M A, Kiviat N, Holmes K K, Eschenbach D A. A case-controlled study of chorioamnionic infection and histologic chorioamnionitis in prematurity.  N Engl J Med. 1988;  319 972-978
  CrossrefPubMedGoogle Scholar
• 22 Glasson J H, Woods W H. Immunoglobulin proteases in bacteria associated with bacterial vaginosis.  Aust J Med Lab Sci. 1988;  9 63-65
  PubMedGoogle Scholar
• 23 McGregor J A, French J I, Jones W et al.. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream.  Am J Obstet Gynecol. 1994;  170 1048-1060
  PubMedGoogle Scholar
• 24 Katsura M, Ito A, Hirakawa S, Mori Y. Human recombinant interleukin 1 (alpha) increases biosynthesis of collagenase and hyaluronic acid in cultured human chorionic cells.  FEBS Lett. 1989;  244 315-318
  CrossrefPubMedGoogle Scholar
• 25 So T, Ito A, Sato T, Mori Y, Hirakawa S. Tumor necrosis factor-(alpha) stimulates the biosynthesis of matrix metalloproteinases and plasminogen activator in cultured human chorionic cells.  Biol Reprod. 1992;  46 772-778
  PubMedGoogle Scholar
• 26 Tjugum J, Norstrom A. The influence of prostaglandin E2 and oxytocin on the incorporation of [3H]proline and [3H]glucosamine in the human amnion.  Eur J Obstet Gynecol Reprod Biol. 1985;  19 137-143
  CrossrefPubMedGoogle Scholar
• 27 DiBattista J A, Pelltier J P, Zafarullah M, Fujimoto N, Obata K, Martel-Pelletier J. Coordinate regulation of matrix metalloproteinases and tissue inhibitor of metalloproteinase expression in human synovial fibroblasts.  J Rheumatol Suppl. 1995;  43 123-128
  PubMedGoogle Scholar
• 28 Guller S, Kong L, Wozniak R, Lockwood C J. Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: a potential role in preterm rupture of the fetal membranes.  J Clin Endocrinol Metab. 1995;  80 2244-2250
  CrossrefPubMedGoogle Scholar
• 29 McLaren J, Taylor D J, Bell S C. Increased incidence of apoptosis in non-labor affected cytotrophoblast cells in term fetal membranes overlying the cervix: implications for preterm birth.  Hum Reprod. 1999;  14 2895-2900
  CrossrefPubMedGoogle Scholar
• 30 Allen S. Tocolytic therapy in preterm PROM.  Clin Obstet Gynecol. 1998;  41 842-848
  CrossrefPubMedGoogle Scholar
• 31 Johnson J W, Daikoku N H, Niebyl J R et al.. Premature rupture of membranes and prolonged latency.  Obstet Gynecol. 1981;  57 547-556
  PubMedGoogle Scholar
• 32 Lewis D F, Major C A, Towers C V, Asrat T, Harding J A, Garite T J. Effects of digital vaginal examinations on latency period in preterm premature rupture of membranes.  Obstet Gynecol. 1992;  80 630-634
  PubMedGoogle Scholar
• 33 Alexander J M, Mercer B M, Miodovnik M et al.. The impact of digital cervical examination on expectantly managed preterm rupture of membranes.  Am J Obstet Gynecol. 2000;  183 1003-1007
  CrossrefPubMedGoogle Scholar
• 34 Fanaroff A A, Wright L L, Stevenson D K et al.. Very-low-birth-weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, May 1991-1992.  Am J Obstet Gynecol. 1995;  173 1423-1431
  CrossrefPubMedGoogle Scholar
• 35 McGregor J A, French J I, Seo K. Antimicrobial therapy in preterm premature rupture of membranes: results of a prospective, double-blind, placebo-controlled trial of erythromycin.  Am J Obstet Gynecol. 1991;  165 632-640
  PubMedGoogle Scholar
• 36 Mercer B M, Arhheart K L. Antimicrobial therapy in expectant management of preterm premature rupture of the membranes.  Lancet. 1995;  346 1271-1279
  CrossrefPubMedGoogle Scholar
• 37 Mercer B M, Miodovnik M, Thurnau G R et al.. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes.  JAMA. 1997;  278 989-995
  CrossrefPubMedGoogle Scholar
• 38 Kenyon S L, Taylor D J, Tarnow-Mordi W et al.. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomized trial.  Lancet. 2001;  357 979-988
  CrossrefPubMedGoogle Scholar
• 39 Leveno K J, Cox K, Roark M L. Cervical dilatation and prematurity revisited.  Obstet Gynecol. 1986;  68 434-435
  PubMedGoogle Scholar
• 40 National Institutes of Health Consensus Development Panel .Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH publication No. 95-3784. Bethesda, MD; National Institute of Child Health and Human Development November 1994
  Google Scholar
• 41 Garite T J, Keegan K A, Freeman R K, Nageotte M P. A randomized trial of ritodrine tocolysis versus expectant management in patients with premature rupture of membranes at 25 to 30 weeks of gestation.  Am J Obstet Gynecol. 1987;  157 388-393
  PubMedGoogle Scholar
• 42 Weiner C P, Renk K, Klugman M. The therapeutic efficacy and cost effectiveness of aggressive tocolysis for premature labor associated with premature rupture of the membranes.  Am J Obstet Gynecol. 1988;  159 216-222
  PubMedGoogle Scholar
• 43 Mercer B M, Crocker L G, Boe N M, Sibai B M. Induction versus expectant management in premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks: a randomized trial.  Am J Obstet Gynecol. 1993;  169 775-782
  PubMedGoogle Scholar
• 44 Cox S M, Leveno K J. Intentional delivery versus expectant management with preterm ruptured membranes at 30-34 weeks gestation.  Obstet Gynecol. 1995;  86 875-879
  CrossrefPubMedGoogle Scholar
• 45 Naef R W, Albert J R, Ross E L, Weber B M, Martin R W, Morrison J C. Premature rupture of membranes at 34 to 37 weeks gestation: aggressive versus conservative management.  Am J Obstet Gynecol. 1998;  178 126-130
  PubMedGoogle Scholar
• 46 Mercer B M, Goldenberg R L, Moawad A H et al.. The Preterm Prediction Study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome.  Am J Obstet Gynecol. 1999;  181 1216-1221
  CrossrefPubMedGoogle Scholar
• 47 Ramsey P S, Nuthalapaty F S, Lu G, Ramin S, Nuthalapaty E S, Ramin K D. Contemporary management of preterm premature rupture of membranes (PPROM): a survey of maternal-fetal medicine providers.  Am J Obstet Gynecol. 2004;  191 1497-1502
  CrossrefPubMedGoogle Scholar
• 48 Nuthalapaty F S, Ramsey P S, Lu G, Ramin S M, Nuthalapaty E S, Ramin K D. Contemporary management of PPROM: does practice setting make a difference?.  Am JObstet Gynecol. 2003;  198 S176
  PubMedGoogle Scholar
• 49 Yoon B H, Jun J K, Romero R et al.. Amniotic fluid inflammatory cytokines (interleukin 6, interleukin 1B, and tumor necrosis factorα), neonatal brain white matter lesions, and cerebral palsy.  Am J Obstet Gynecol. 1997;  177 19-26
  CrossrefPubMedGoogle Scholar
• 50 Yoon B H, Romero R, Park J S, Kim C J, Choi J H, Han T R. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years.  Am J Obstet Gynecol. 2000;  182 675-681
  CrossrefPubMedGoogle Scholar
• 51 Vigneswaran R. Infection and preterm birth: evidence of a common causal relationship with bronchopulmonary dysplasia and cerebral palsy.  J Paediatr Child Health. 2000;  36 293-296
  PubMedGoogle Scholar
• 52 Nelson K B, Ellenberg J H. Antecedents of cerebral palsy: multivariate analysis of risk.  N Engl J Med. 1986;  315 81-86
  PubMedGoogle Scholar
• 53 Gaudet L M, Smith G N. Cerebral palsy and chorioamnionitis: the inflammatory cytokine link.  Obstet Gynecol Surv. 2001;  56 433-436
  CrossrefPubMedGoogle Scholar
• 54 Wu Y W, Colford Jr J M. Chorioamnionitis as a risk factor for cerebral palsy: a meta-analysis.  JAMA. 2000;  284 1417-1424
  CrossrefPubMedGoogle Scholar
• 55 Crowley P. Prophylactic corticosteroids for preterm birth.  Cochrane Database Syst Rev. 2000;  2 , CD000065
  PubMedGoogle Scholar
• 56 Crowley P A. Antenatal corticosteroid therapy: a meta-analysis of randomized trials, 1972 to 1994.  Am J Obstet Gynecol. 1995;  173 322-335
  CrossrefPubMedGoogle Scholar
• 57 Morales W J, Diebel D, Lazar A J, Zadrozny D. The effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome in preterm gestations with premature rupture of membranes.  Am J Obstet Gynecol. 1986;  154 591-595
  PubMedGoogle Scholar
• 58 Effect of corticosteroids for fetal maturatin on perinatal outcomes.  NIH Consens Statement. 1994;  12 1-24
  PubMedGoogle Scholar
• 59 Gardner M O, Papile L A, Wright L L. Antenatal corticosteroids in pregnancies complicated by preterm premature rupture of membranes.  Obstet Gynecol. 1997;  90 851-853
  CrossrefPubMedGoogle Scholar
• 60 Imseis H M, Iams J D. Glucocorticoid use in patients with preterm premature rupture of the fetal membranes.  Semin Perinatol. 1996;  20 439-450
  PubMedGoogle Scholar
• 61 Vermillion S T, Soper D E, Bland M L, Newman R B. Effectiveness of antenatal corticosteroid administration after preterm premature rupture of the membranes.  Am J Obstet Gynecol. 2000;  183 925-929
  CrossrefPubMedGoogle Scholar
• 62 Pattinson R C, Makin J D, Funk M et al.. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre, double-blind, placebo-controlled, randomized trial. Dexiprom Study Group.  S Afr Med J. 1999;  89 865-870
  PubMedGoogle Scholar
• 63 Harding J E, Pang J-M, Knight D B, Liggins G C. Do antenatal corticosteroids help in the setting of preterm rupture of membranes?.  Am J Obstet Gynecol. 2001;  184 131-139
  CrossrefPubMedGoogle Scholar
• 64 Liggins G C, Howie R N. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants.  Pediatrics. 1972;  50 515-525
  PubMedGoogle Scholar
• 65 Banks B A, Cnaan A, Morgan M A et al.. Multiple courses of antenatal corticosteroids and outcome of premature neonates.  Am J Obstet Gynecol. 1999;  181 709-717
  PubMedGoogle Scholar
• 66 Thorp J A, Jone A M, Hunt C, Clark R. The effect of multidose antenatal betamethasone on maternal and infant outcomes.  Am J Obstet Gynecol. 2001;  184 196-202
  CrossrefPubMedGoogle Scholar
• 67 Lee M-J, Davies J, Guinn D et al.. Single versus weekly courses of antenatal corticosteroids in preterm premature rupture of membranes.  Obstet Gynecol. 2004;  103 274-281
  CrossrefPubMedGoogle Scholar
• 68 Simchen M J, Alkazaleh F, Adamson S L et al.. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction.  Am J Obstet Gynecol. 2004;  190 296-304
  CrossrefPubMedGoogle Scholar
• 69 Christensen K K, Ingemarsson I, Leideman T, Solum T, Svenningsen N. Effect of ritodrine on labor after premature rupture of the membranes.  Obstet Gynecol. 1980;  55 187-190
  PubMedGoogle Scholar
• 70 Levy D L, Warsof S L. Oral ritodrine and preterm premature rupture of membranes.  Obstet Gynecol. 1985;  66 621-623
  PubMedGoogle Scholar
• 71 Wapner for the NICHD MFMU Network . A randomized trial of single vs weekly courses of corticosteroids.  Am J Obstet Gynecol. 2003;  189 S56
  PubMedGoogle Scholar
• 72 Guinn D A, Atkinson M W, Sullivan L et al.. Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: a randomized controlled trial.  JAMA. 2001;  286 1581-1587
  CrossrefPubMedGoogle Scholar
• 73 National Institutes of Health (NIH) Consensus Statement . Antenatal corticosteroids revisited: repeat courses.  NIH Consens Statement. 2000;  17 1-18
  PubMedGoogle Scholar
• 74 Matsuda Y, Ikenoue T, Hokanishi H. Premature rupture of the membranes-aggressive versus conservative approach: effect of tocolytic and antibiotic therapy.  Gynecol Obstet Invest. 1993;  36 102-107
  PubMedGoogle Scholar
• 75 Mercer B, Moretti M, Rogers R, Sibai B. Antibiotic prophylaxis in preterm premature rupture of membranes: prospective randomized double-blind trial of 220 patients.  Am J Obstet Gynecol. 1992;  166 794-802
  PubMedGoogle Scholar
• 76 American College of Obstetricians and Gynecologists . ACOG practice bulletin number 47, October 2003: Prophylactic antibiotics in labor and delivery.  Obstet Gynecol. 2003;  102 875-882
  CrossrefPubMedGoogle Scholar
• 77 Andrews W W, Goldenberg R L, Hauth J C. Preterm labor: emerging role of genital tract infections.  Infect Agents Dis. 1995;  4 196-211
  PubMedGoogle Scholar
• 78 Goldenberg R L, Hauth J C, Andrews W W. Intrauterine infection and preterm delivery.  N Engl J Med. 2000;  342 1500-1507
  CrossrefPubMedGoogle Scholar
• 79 Yoon B H, Romero R, Yang S H et al.. Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia.  Am J Obstet Gynecol. 1996;  174 1433-1440
  CrossrefPubMedGoogle Scholar
• 80 Jobe A H, Ikegami M. Mechanisms initiating lung injury in the preterm.  Early Hum Dev. 1998;  53 81-94
  CrossrefPubMedGoogle Scholar
• 81 American College of Obstetricians and Gynecologists . ACOG committee opinion number 279, December 2002: prevention of early-onset group B streptococcal disease in newborns.  Obstet Gynecol. 2002;  100 1405-1412
  CrossrefPubMedGoogle Scholar
• 82 Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC.  MMWR Recomm Rep. 2002;  51 1-22
  PubMedGoogle Scholar
• 83 Matteson J J, Ramsey P S, Brumfield C G, Carlo W. Preterm premature rupture of membranes: is there an optimal delivery gestational age?.  Obstet Gynecol. 2002;  99 74S-75S
  PubMedGoogle Scholar

Kirk D RaminM.D. 

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Minnesota

420 Delaware Street SE, Minneapolis, MN 55455